All Costs, No Benefits: How TRIPS plus intellectual property rules in the US-Jordan FTA affect access to medicines

Thumbnail
Name:
bp102-all-costs-no-benefits-tr ...
Size:
207.7Kb
Format:
PDF
Description:
English paper
Download
Thumbnail
Name:
bp102-all-costs-no-benefits-tr ...
Size:
539.5Kb
Format:
PDF
Description:
Arabic paper
Download
Thumbnail
Name:
bp102-all-costs-no-benefits-TR ...
Size:
242.0Kb
Format:
PDF
Description:
French paper
Download
Thumbnail
Name:
bp102-all-costs-no-benefits-TR ...
Size:
248.4Kb
Format:
PDF
Description:
Spanish paper
Download
View more files
Author(s)
Malpani, Rohit
Publication date
2007-03-21
Subject
Health
Trade
Keywords
Access to medicines
TRIPS and patents
World Trade Organisation
WTO
Country
United States
Jordan

Metadata
Show full item record
Publisher(s)
Oxfam International
Document type
Briefing paper
Description
The USA continues to impose TRIPS-plus rules on developing countries, thus preventing poor people from accessing inexpensive, generic medicines. Jordan was required under the terms of its WTO accession package and its free trade agreement (FTA) with the USA to introduce TRIPS-plus rules. Medicine prices have increased drastically, and TRIPS-plus rules were partly responsible for this increase. Furthermore, stricter levels of intellectual property protection have conferred few benefits with respect to foreign direct investment, domestic research and development, or accelerating introduction of new, effective medicines. Medicine prices will continue to rise in Jordan, but the country will be unable to use TRIPS safeguards to reduce their cost. Other developing countries implementing or considering FTAs with TRIPS-plus rules should consider the consequences for public health.
Pages
37
ISBN
978-1-84814-206-0
URI
http://hdl.handle.net/10546/114080
Additional Links
https://policy-practice.oxfam.org.uk/publications/all-costs-no-benefits-how-trips-plus-intellectual-property-rules-in-the-us-jord-114080
Collections